Related Experiment Videos
New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2
Abstract:
The clinical use of Biological Response Modifiers (BRMs) in the diagnosis and treatment of cancer is rapidly changing the practice of oncology nursing. Recent key scientific advances have allowed production of unique natural agents useful in oncology as well as other diseases. An understanding of basic immunology is essential to the nurse involved in experimental clinical trials using BRMs. Interferons, Interleukins and Monoclonal Antibodies as well as other BRMs, all have biological/immunological interactions that must be understood. Nursing implications, I.V. techniques, and risk management as well as the scope of institutional interactions related to clinical trials with BRMs are described.
Insights
Biological Response Modifiers (BRMs) are revolutionizing cancer care, requiring oncology nurses to understand basic immunology for clinical trials. Key BRMs like interferons and interleukins have complex interactions demanding careful nursing management.
Area of Science:
- Oncology Nursing
- Immunology
- Cancer Therapeutics
Background:
- Biological Response Modifiers (BRMs) are increasingly utilized in cancer diagnosis and treatment.
- Advances in biotechnology enable the production of novel natural agents for various diseases, including cancer.
- Oncology nursing practice is significantly impacted by the evolving clinical applications of BRMs.
Purpose of the Study:
- To highlight the essential role of basic immunology knowledge for nurses managing patients in BRM clinical trials.
- To describe the biological and immunological interactions of key BRMs such as interferons, interleukins, and monoclonal antibodies.
- To outline the nursing implications, including IV techniques, risk management, and institutional collaboration, for BRM clinical trials.
Main Methods:
- Review of current scientific literature on BRMs and their clinical applications in oncology.
- Analysis of immunological mechanisms underlying the action of BRMs.
- Description of practical nursing considerations for administering BRMs and managing patients in clinical trials.
Main Results:
- Understanding BRM immunology is crucial for effective nursing care in experimental cancer treatment.
- Specific BRMs (Interferons, Interleukins, Monoclonal Antibodies) possess distinct biological interactions requiring specialized knowledge.
- Comprehensive nursing management strategies encompass administration techniques, risk mitigation, and inter-institutional coordination.
Conclusions:
- Nurses require a solid foundation in immunology to effectively participate in clinical trials involving Biological Response Modifiers.
- The safe and effective use of BRMs in oncology necessitates a thorough understanding of their mechanisms and potential side effects.
- This knowledge empowers nurses to optimize patient care and outcomes in the evolving landscape of cancer therapy.